RxSight, Inc. Proceeds from Sale of Notes Receivable
RxSight, Inc. (RXST) reported Proceeds from Sale of Notes Receivable of $136.00 thousand for the 12-month period ending 2021-12-31, per its 10-K filed 2023-03-06.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfNotesReceivable · last filed 2023-03-06
- RxSight, Inc. proceeds from sale of notes receivable for the quarter ending 2021-09-30 was $136.00K.
- RxSight, Inc. proceeds from sale of notes receivable for fiscal 2021 was $136.00K.
| Period end | Proceeds from Sale of Notes Receivable 3 month | Proceeds from Sale of Notes Receivable 12 month |
|---|---|---|
| 2021-12-31 | $136.00K 10-K · filed 2023-03-06 | |
| 2021-09-30 | $136.00K 10-Q · filed 2022-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Innovative Eyewear Inc (LUCY) | United States | $0.008B | |
| STAAR SURGICAL CO (STAA) | United States | $0.957B | 362.70 |
| National Vision Holdings, Inc. (EYE) | United States | $1.297B | |
| Warby Parker Inc. (WRBY) | United States | $2.970B | |
| Bausch & Lomb Corp (BLCO) | Canada | $6.008B | -34.58 |
| COOPER COMPANIES, INC. (COO) | United States | $10.533B | 24.09 |